Published in Nat Med on February 14, 2010
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol (2010) 2.64
Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature (2013) 2.33
The role of EZH2 in tumour progression. Br J Cancer (2011) 2.33
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest (2012) 2.03
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell (2013) 1.75
PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature (2014) 1.60
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
Mechanosensitive pannexin-1 channels mediate microvascular metastatic cell survival. Nat Cell Biol (2015) 1.51
Targeting EZH2 in cancer. Nat Med (2016) 1.51
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res (2010) 1.46
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer. Endocr Relat Cancer (2014) 1.45
NF-kB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res (2011) 1.42
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell (2012) 1.34
ROCK inhibitor Y-27632 suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells and increases their cloning efficiency. PLoS One (2011) 1.34
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene (2011) 1.32
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J (2012) 1.32
Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27
ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc Natl Acad Sci U S A (2013) 1.26
The role of EZH2 in the regulation of the activity of matrix metalloproteinases in prostate cancer cells. PLoS One (2012) 1.25
Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology (2010) 1.22
EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci U S A (2014) 1.18
Histone modifiers in cancer: friends or foes? Genes Cancer (2011) 1.10
Contributions of epithelial-mesenchymal transition and cancer stem cells to the development of castration resistance of prostate cancer. Mol Cancer (2014) 1.07
Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ (2011) 1.07
The genomic landscape of prostate cancer. Front Endocrinol (Lausanne) (2012) 1.07
Histone demethylase RBP2 is critical for breast cancer progression and metastasis. Cell Rep (2014) 1.04
Nonredundant functions for Ras GTPase-activating proteins in tissue homeostasis. Sci Signal (2013) 1.03
PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep (2013) 1.02
Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop. Mol Cell Biol (2012) 1.02
Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death Dis (2012) 1.02
AIP1 prevents graft arteriosclerosis by inhibiting interferon-γ-dependent smooth muscle cell proliferation and intimal expansion. Circ Res (2011) 1.02
EZH2, an epigenetic driver of prostate cancer. Protein Cell (2013) 1.02
Molecular pathways and targets in prostate cancer. Oncotarget (2014) 1.00
MicroRNA-mediated regulation of the angiogenic switch. Curr Opin Hematol (2011) 1.00
Neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis. Proc Natl Acad Sci U S A (2014) 0.98
Genomic loss of the putative tumor suppressor gene E2A in human lymphoma. J Exp Med (2011) 0.97
Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene (2014) 0.97
SIRT7 inactivation reverses metastatic phenotypes in epithelial and mesenchymal tumors. Sci Rep (2015) 0.95
Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer. Cancer Sci (2014) 0.95
EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One (2012) 0.94
Functional parsing of driver mutations in the colorectal cancer genome reveals numerous suppressors of anchorage-independent growth. Cancer Res (2011) 0.94
The role of epithelial plasticity in prostate cancer dissemination and treatment resistance. Cancer Metastasis Rev (2014) 0.94
Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer (2016) 0.93
Genome-wide analysis of Pax8 binding provides new insights into thyroid functions. BMC Genomics (2012) 0.93
Impaired PRC2 activity promotes transcriptional instability and favors breast tumorigenesis. Genes Dev (2015) 0.93
Epigenetics in prostate cancer. Prostate Cancer (2011) 0.92
c-Myc expression and MEK1-induced Erk2 nuclear localization are required for TGF-beta induced epithelial-mesenchymal transition and invasion in prostate cancer. Carcinogenesis (2012) 0.92
The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Clin Cancer Res (2013) 0.92
Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU Int (2010) 0.91
The role of homeostatic regulation between tumor suppressor DAB2IP and oncogenic Skp2 in prostate cancer growth. Oncotarget (2014) 0.90
EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. PLoS One (2013) 0.89
3'LIFE: a functional assay to detect miRNA targets in high-throughput. Nucleic Acids Res (2014) 0.89
Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer (2015) 0.89
Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition. Oncogenesis (2012) 0.88
Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance. Oncotarget (2014) 0.88
PPM1A is a RelA phosphatase with tumor suppressor-like activity. Oncogene (2013) 0.88
Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol (2013) 0.88
Signal transduction in cancer. Cold Spring Harb Perspect Med (2015) 0.88
PRC2/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS One (2012) 0.88
Activation of nuclear factor κB (NF-κB) in prostate cancer is mediated by protein kinase C epsilon (PKCepsilon). J Biol Chem (2012) 0.88
Cells of origin for cancer: an updated view from prostate cancer. Oncogene (2012) 0.87
Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One (2012) 0.87
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PLoS One (2014) 0.87
RREB1 transcription factor splice variants in urologic cancer. Am J Pathol (2011) 0.87
Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Res (2014) 0.87
Negative regulation of DAB2IP by Akt and SCFFbw7 pathways. Oncotarget (2014) 0.87
Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin. Oncotarget (2014) 0.86
TRAF2 is an NF-κB-activating oncogene in epithelial cancers. Oncogene (2013) 0.86
Identifying the Ubiquitin Ligase complex that regulates the NF1 tumor suppressor and Ras. Cancer Discov (2013) 0.85
Validation of DAB2IP methylation and its relative significance in predicting outcome in renal cell carcinoma. Oncotarget (2016) 0.85
AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Res (2014) 0.85
EZH2 in Bladder Cancer, a Promising Therapeutic Target. Int J Mol Sci (2015) 0.85
Interrogating genomic and epigenomic data to understand prostate cancer. Biochim Biophys Acta (2012) 0.85
Update of research on the role of EZH2 in cancer progression. Onco Targets Ther (2013) 0.84
Smarca4 ATPase mutations disrupt direct eviction of PRC1 from chromatin. Nat Genet (2016) 0.84
Targeting Cancer Stem Cells in Castration-Resistant Prostate Cancer. Clin Cancer Res (2015) 0.83
Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies. Oncogene (2016) 0.83
EZH2 regulates cofilin activity and colon cancer cell migration by targeting ITGA2 gene. PLoS One (2014) 0.83
JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. Cancer Res (2016) 0.83
Dab2IP GTPase activating protein regulates dendrite development and synapse number in cerebellum. PLoS One (2013) 0.83
Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis. BMC Cancer (2016) 0.82
mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients. J Transl Med (2011) 0.82
Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system. AAPS J (2014) 0.82
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget (2015) 0.82
microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells. Oncol Lett (2015) 0.81
AIP1 in graft arteriosclerosis. Trends Cardiovasc Med (2011) 0.81
Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell (2010) 0.81
The positive feedback between Snail and DAB2IP regulates EMT, invasion and metastasis in colorectal cancer. Oncotarget (2015) 0.81
Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer. Oncotarget (2016) 0.81
Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci (2015) 0.81
Histone methyltransferase and histone methylation in inflammatory T-cell responses. Immunotherapy (2013) 0.81
The role of wild type RAS isoforms in cancer. Semin Cell Dev Biol (2016) 0.81
Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing. Oncotarget (2015) 0.80
Smurf1 regulation of DAB2IP controls cell proliferation and migration. Oncotarget (2016) 0.80
Neural crest specification and migration independently require NSD3-related lysine methyltransferase activity. Mol Biol Cell (2014) 0.80
Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-κB signaling. PLoS One (2012) 0.80
AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis. Cancer Res (2015) 0.79
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer (2002) 34.99
Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell (2004) 31.38
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Shared principles in NF-kappaB signaling. Cell (2008) 20.96
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Microenvironmental regulation of metastasis. Nat Rev Cancer (2008) 15.76
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A (2004) 10.99
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res (2008) 6.46
Prostate cancer. N Engl J Med (2003) 5.91
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Prognosis of cancers associated with venous thromboembolism. N Engl J Med (2000) 4.51
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A (2005) 3.49
Requirement of NF-kappaB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science (1997) 3.32
Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res (2003) 2.91
Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res (1999) 2.88
Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73
Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem (2005) 2.58
Gene expression analysis of prostate cancers. Mol Carcinog (2002) 2.51
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res (2002) 2.46
BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer (2006) 2.45
Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res (2004) 2.32
Adaptation versus selection: the origins of metastatic behavior. Cancer Res (2007) 2.08
Pten inactivation and the emergence of androgen-independent prostate cancer. Cancer Res (2007) 1.59
AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. J Biol Chem (2004) 1.56
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer? Cancer Cell (2002) 1.56
Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem (2002) 1.55
Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One (2009) 1.54
Mouse models of prostate carcinogenesis. Trends Genet (2002) 1.52
Aberrant promoter methylation of human DAB2 interactive protein (hDAB2IP) gene in lung cancers. Int J Cancer (2005) 1.45
Integrative biology of prostate cancer progression. Annu Rev Pathol (2006) 1.45
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer. Clin Cancer Res (2004) 1.39
Epithelial-mesenchymal transition: NF-kappaB takes center stage. Cell Cycle (2004) 1.38
Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB. Mol Cell Biol (2000) 1.31
BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PLoS One (2008) 1.28
ras gene mutations in human prostate cancer. Cancer Res (1990) 1.24
Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer (2005) 1.21
Activated ras alleles in human carcinoma of the prostate are rare. Cancer Res (1991) 1.17
GAPs in growth factor signalling. Growth Factors (2005) 1.12
Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol (2006) 0.97
GEFs in growth factor signaling. Growth Factors (2007) 0.92
Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer (2004) 0.89
Radical prostatectomy for clinically localized prostate cancer: local tumor extension and prognosis. Int J Urol (1996) 0.80
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med (2005) 15.42
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell (2005) 15.06
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med (2004) 13.57
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Restoration of p53 function leads to tumour regression in vivo. Nature (2007) 12.62
Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell (2008) 12.29
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell (2004) 9.41
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell (2004) 8.16
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Mammalian Sir2 homolog SIRT3 regulates global mitochondrial lysine acetylation. Mol Cell Biol (2007) 7.97
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature (2005) 6.86
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med (2015) 5.71
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
Cyclin E ablation in the mouse. Cell (2003) 5.58
Millisecond-timescale optical control of neural dynamics in the nonhuman primate brain. Neuron (2009) 5.50
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Mosaic analysis with double markers reveals tumor cell of origin in glioma. Cell (2011) 4.78
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn (2006) 4.68
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet (2013) 4.48
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins. Nature (2012) 4.35
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal (2010) 4.15
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Many ribosomal protein genes are cancer genes in zebrafish. PLoS Biol (2004) 3.99
p63 protects the female germ line during meiotic arrest. Nature (2006) 3.98
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. J Mol Diagn (2006) 3.98
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature (2009) 3.93
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80
Essential role for the peroxiredoxin Prdx1 in erythrocyte antioxidant defence and tumour suppression. Nature (2003) 3.77